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Objectives
To compare long-term adherence to antiretroviral therapy in an HIV service, as measured by
self-report and by pharmacy records. To determine the level of adherence by each measure required
to suppress viral load in a majority of patients.
Methods
The percentage of prescribed doses taken was calculated from (a) the number of missed doses in the
previous 28 days reported by patients in a questionnaire at each clinic visit, and (b) pharmacy
dispensing records. These were compared with each other and with HIV viral load data.
Results
Mean adherence was 96.2% by pharmacy record over 44 months and 98.6% by self-report over 25
months. The two methods correlated with each other (Po0.001) and the proportion of patients with
viral load o400 HIV-1 RNA copies/mL increased with adherence as measured by self-report
(P 5 0.001) and pharmacy record (P 5 0.004). Fewer than 60% of patients always had viral loads
o400 copies/mL if adherence fell below 95% (pharmacy record) or 97% (self-report). Adherence was
higher for once-daily than for twice-daily therapy (by pharmacy record: 97.2% vs. 96.0%;
Po0.001). Adherence by both measures increased over time.
Conclusions
Self-reported antiretroviral adherence correlates with pharmacy dispensing records and predicts
suppression of viral load at levels  97%. It is practical to adopt this into routine HIV clinical care.
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Introduction
One of the most important issues in managing patients with
HIV therapy is adherence to this therapy [1]. Extraordina-
rily high levels of adherence, of greater than 95%, need to
be achieved and maintained for many years if treatment is
to be successful and the development of resistance is to be
prevented [2]. Not only are these levels much higher than
are needed for other chronic conditions such as hyperten-
sion, but even temporary failure to adhere carries the risk
of long-term treatment failure [2]. Clinical guidelines
recommend, among other things, measuring adherence
regularly, and in most clinics self-report is the only feasible
method [2]. Because most studies have taken place over
short periods and are not necessarily generalizable to a
standard HIV service, it remains unclear what level of
self-reported adherence is sufficient [3].
To answer this question, we assessed the results at our
clinic, where we have measured adherence at every clinical
visit since May 2001. We have noticed that a significant
proportion of patients are reporting 100% adherence but
have a detectable viral load [4]. Our aim was to determine
what level of self-reported adherence was associated with
a decline in viral load and to compare this to another
measure of adherence.
Methods
This was a retrospective audit undertaken at the HIV clinic at
Melbourne Sexual Health Centre. This clinic provides free
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antiretroviral therapy and dispenses over 50% of all
antiretroviral therapy in Victoria. Because other centres in
Melbourne charge $23.80 per item per month, patients at
MSHC frequently return to this centre for every prescription.
Adherence was measured by two methods: self-reported
adherence and an audit of pharmacy records. Self-reported
adherence was measured from May 2001 to August 2003 by
the Every Visit Adherence Questionnaire of the clinic. At
each clinic visit, patients record their number of daily doses
and the number of doses they missed over the last 28 days
[4]. Adherence was calculated as the percentage of doses
taken over each period. For each individual, the average
adherence was calculated for the period for which data were
available. Self-reported adherence was only available for
patients who were seen by practitioners in the clinic. About
half of the patients who receive therapy from our pharmacy
are seen and have prescriptions written elsewhere.
Adherence using pharmacy record was measured by using
the pharmacy computerized dispensing system (STOCCA)
from January 2000 until August 2003. For each patient, the
number of days of therapy prescribed (excluding the last
prescription) was divided by the number of days between
the first and last prescriptions. Adherence levels of more
than 100% were rounded down to 100%. Drugs were
excluded from the analysis if they did not have a standard
dose, the dose varied or they were prescribed infrequently.
Drugs that were included in the analysis were: abacavir
300 mg, didanosine 100, 250 and 400mg, efavirenz 200 and
600 mg, lamivudine 150 mg, Combivir (zidovudine and
lamivudine, GSK, Brentford, UK), nevirapine 200 mg,
stavudine 30 and 40 mg, Trizivir (abacavir, zidovudine and
lamivudine, GSK), tenofovir 300 mg, zidovudine 250 mg,
and lopinavir. Patients were excluded from the analysis if
there was a gap of more than 6 weeks in their medication
supply as these patients were considered more likely to have
obtained medication elsewhere, or to have stopped their
treatment. Once a day treatment was defined as those drugs
licensed as once a day at the time of the study (tenofovir,
didanosine 250 and 400 mg, and efavirenz).
Viral load and CD4 lymphocyte counts were obtained
from the electronic data records of the clinic. When viral
load measurements were compared with adherence, the
average adherence over the entire period was compared with
the proportion of patients who always had a viral load of
less than 400 HIV-1 RNA copies/mL over the entire period.
Analysis
Multiple linear regression was used to determine if the
adherence had changed over the 4-year period, taking
account of repeated measures for each year and once vs
twice a day treatment. A t-test, a w2 test or McNemar’s test
were used for other comparisons depending on whether the
data were continuous or categorical.
Results
Pharmacy record
Between January 2000 and August 2003, 880 patients
received prescriptions for at least one of the selected
antiretroviral drugs through the MSHC pharmacy. Of these,
128 individuals were excluded because they had gaps in
their prescriptions of 6 weeks or more. The mean adherence
over this time was 96.2% and adherence increased
significantly each year (P 5 0.03, Table 1). Adherence was
significantly higher for once a day compared with twice a
day treatment (97.2% vs. 96.0%; Po0.001; Table 2).
Self-report
Between May 2001 and August 2003 there were 488
patients who attended the clinic and were taking anti-
retrovial therapy, and who completed the Every Visit
Adherence Questionnaire. Their mean age was 43 years,
464 were male, 449 were men who had sex with men and
seven were injecting drug users. The mean adherence of
these 488 individuals was 98.6% and the median was
99.7% (range 50% to 100%). The mean adherence increased
significantly between 2001 and August 2003 (P 5 0.005;
Table 1).
Viral load correlation
The viral load measurements were significantly related to
adherence measured by both pharmacy record and self-
report (Po0.004) (Fig. 1). The proportion of patients with
viral load below 400 copies/mL fell below 60% when
adherence fell below 95% (by pharmacy record) and 97%
(by self-report).











2000 95.6 (6.4) 92.2
2001 96.2 (6.1) 94.2 98.1 (3.3) 98.2
2002 96.3 (6.1) 95.0 98.7 (3.0) 99.3
2003 96.6 (6.0) 95.6 99.0 (3.2) 100
Mean adherence (repeated measures) adjusted for times per day increased
significantly over time for pharmacy record (P 5 0.03) and self-report
(P 5 0.005).
SD, standard deviation.
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Correlations between adherence measures
Table 3 shows the correlation between self-report and
pharmacy record, using o95% as nonadherent for phar-
macy record and o97% as nonadherent for self-report.
Pharmacy record identified about twice as many individuals
as nonadherent compared with self-report (27% vs. 14%;
Po0.001).
Discussion
This study of adherence to antiretrovirals in routine clinical
care found higher levels of adherence when adherence was
measured by patient self-report (mean 98.6%) than when it
was measured by pharmacy dispensing records (mean
96.2%). The proportion of patients with viral load
consistently o400 copies/mL fell below 60% at a higher
level of adherence as measured by self-report (97%) than as
measured by pharmacy records (95%). Pharmacy records
also showed that once-daily dosing was associated with
higher levels of adherence than twice-daily dosing, and
adherence measured by both methods increased over time.
We measured long-term adherence by two practical,
inexpensive methods, self-report (2 years 3 months) and
pharmacy records (3 years 8 months), and found clinically
useful levels of adherence required to suppress viral load in
most patients. Electronic measurements such as MEMS
(Medication Event Monitoring System, Aprex Corp., Fremont,
CA, USA) caps are more accurate measures of adherence, but
are too expensive for widespread use [3]. Pharmacy records
are less useful for drugs where the dose may vary. Patients
may have accumulated some pills and this may have masked
occasional nonadherence. However, we examined pharmacy
records over a longer period to reduce the impact of this.
Studies of adherence to antiretrovirals are often cross-
sectional, short-term or within research settings and have
shown that adherence is an important predictor of
successful suppression of viral load. Using the MEMS in a
prospective study with a 6-month mean follow-up,
Paterson [3] found that virological failure rates were lowest
in those taking at least 95% of a regimen containing a
protease inhibitor. This was confirmed by our examination
of longer-term adherence (over 2 years) in unselected
patients in an HIV clinic. A similar review of dispensing
records in a centralized free pharmacy found that
intermittent treatment (dispensing less than 12 months
medication in a year) predicted increased mortality, but this
study did not attempt to distinguish between nonadherence
and interrupted treatment [5]. A correlation has also been
observed between self-reported nonadherence, suboptimal
Table 2 Adherence for once a day regimens compared with twice a
day by pharmacy record
Mean (SD) 25th percentile
Once a day 97.2 (5.4) 96.8
Twice a day 96.0 (6.3) 93.8
Total 96.2 (6.2)
Po0.001 for mean adherence, for once a day compared with twice a day.
There were 378 patients taking at least one once a day treatment, and 749


























































Fig. 1 Percentage of patients with viral load (VL) o400 copies/mL
at increasing levels of adherence by pharmacy record or self-report.
Defined as the percentage with VL below 400 copies/mL for all
measurements in any one individual. Self-reported adherence
(P 5 0.001) and pharmacy record adherence (P 5 0.004 by w2 test)
both significantly increased as the percentage with undetectable
VL rose.




o97% 29 30 59
97% 83 272 355
Total 112 302 414
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plasma drug concentrations and virological failure in an
Italian cohort followed for 96 weeks [6].
We found that once a day medication had higher levels of
adherence as measured by pharmacy record. It is important
to appreciate, however, that we looked at individual drugs
separately, and not at the whole regime. At the time of this
study, few patients were taking mediation that could be
taken once a day and at the same time of the day. However,
our finding suggests that medication that can be taken only
once a day is associated with higher levels of adherence,
even if this is not necessarily what the patients feel will be
the easiest to take [7].
Our study excluded 128 patients who had gaps in their
prescriptions of greater than 6 weeks. We were not able to
determine the reason for these gaps, but if patients had had
their medication stopped because of poor adherence then
the overall estimate of adherence in our study will be
artificially high.
HIV clinics need to aim for high levels of adherence, and
the critical levels we found (97% by self-report) imply that
patients reporting one missed dose per 33 doses need extra
support. This approximates to missing one dose a month
for once-daily dosing or two per month for twice-daily
dosing. The finding that patients report higher levels of
adherence than pharmacy records indicate explains, at
least partly, our observation that some patients fail to
suppress their viral load despite reporting 100% adherence.
Pre-existing resistance and inadequate plasma concentra-
tions of drug are also likely to contribute to this.
Improvements in adherence over time as measured by
both methods may reflect a response by patients both to
our regular questionnaire and to an adherence-support
programme running in the clinic. The questionnaire and
programme may also have caused some patients to
overestimate their adherence. Measurement of adherence
and support to improve it should now become a routine
part of HIV clinical care and are likely to be cheaper than
changing or intensifying antiretroviral combinations.
Future research will help identify the critical levels of
adherence for different antiretroviral classes and different
clinical situations. For example, a person with a high
pretreatment viral load on a combination including a
nonnucleoside reverse transcriptase inhibitor may need to
maintain higher levels of adherence than someone with a
lower pretreatment viral load whose combination includes
a protease inhibitor.
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